Good morning from San Diego. I’m Jonathan Wosen, STAT’s West Coast biotech reporter, and I’m picking up the baton from Allison as we continue to fill in for Ed this week. I’m not a coffee drinker, but I’ve poured myself a cup of water. No ice, though, as I find it dilutes the flavor. Jokes aside, here are some newsy items for you to peruse this morning.
Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight, according to STAT. Over the last five years, the venture capital firm, whose parent company manages $280 billion from the United Arab Emirates’ vast oil business, has risen from obscurity and earned the respect of observers who say it could be the next potential breakout star in the investment world.
Pfizer is raiding Alphabet company Verily’s C-suite for its first global chief marketing officer, Endpoints tells us. The pharma giant will be bringing on Andreas “Drew” Panayiotou, who is currently chief marketing officer at Verily, a health technology company. Panayiotou, who will be tasked with building the 26,000-employee company’s commercial infrastructure, joins a short list of chief marketing officers inside pharma companies.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect